# Scientists found a hidden brain signal that may make GLP-1 weight loss last longer

> Researchers at the National Institutes of Health have identified a brain-cell signaling pathway that helps explain how semaglutide drives weight loss in mice, according to an official announcement from NIH researchers. The work points to a possible way to extend the effects...

Canonical URL: https://www.argo.net/scientists-found-a-hidden-brain-signal-that-may-make-glp-1-weight-loss-last-longer/
Byline: National Institutes of Health
Published: 2026-07-13T07:00:03+00:00
Categories: Health, News

![Semaglutide-style injection pen used in metabolic medicine research](https://www.argo.net/wp-content/uploads/2026/06/glp-1_injection_weight_loss.jpg)

Researchers at the National Institutes of Health have identified a brain-cell signaling pathway that helps explain how semaglutide drives weight loss in mice, according to an official announcement from [NIH researchers](https://www.nih.gov/news-events/news-releases/nih-researchers-identify-avenue-enhanced-glp-1-induced-weight-loss). The work points to a possible way to extend the effects of GLP-1 drugs, while also giving scientists a closer look at why responses to these medicines can differ from one patient to another.

The study focused on what happens inside neurons after exposure to semaglutide, a widely used **GLP-1 receptor agonist**. Scientists already know that these drugs act on brain regions involved in appetite. The NIH team looked deeper, at the molecular signals that unfold inside the targeted cells.

That level of detail matters because GLP-1 drugs have become central tools in obesity and diabetes care. Many people lose substantial weight, yet the response can vary. Weight loss also often slows over time. By tracing the signal inside neurons, the researchers found a candidate mechanism that could help explain those patterns.

## Semaglutide's signal inside brain cells

Semaglutide works by activating GLP-1 receptors, which sit on certain cells and respond to a hormone signal linked to blood sugar and appetite. In this study, the NIH team examined GLP-1 receptor-expressing neurons in the hindbrain of mice. A key focus was the **area postrema**, a small brain region that contains appetite-related circuits.

Using **fluorescence imaging** in living mouse brain tissue, the researchers watched how cells responded after semaglutide exposure. This allowed them to follow intracellular activity in real time. The method gave them a direct view of signaling events that are usually hidden inside neurons.

One molecule stood out: **cyclic adenosine monophosphate**, commonly called cAMP. This molecule acts as a messenger inside cells. In the area postrema, semaglutide increased cAMP in GLP-1-responsive neurons and that signal was tied to the drug's weight-loss effect in the mouse experiments.

Andrew Lutas, Ph.D., an investigator at NIH's National Institute of Diabetes and Digestive and Kidney Diseases, described the reason for looking at this inner machinery. "We know much less about the nuts and bolts of what goes on within the neurons that these medications target," he said.

## Why some neurons keep responding

The neurons did have a striking feature. They responded to semaglutide in different ways. Some cells kept their cAMP levels elevated while the drug was present. Other cells showed only a temporary rise before the signal faded.

Michael Krashes, Ph.D., a senior investigator at NIDDK and co-corresponding author of the study, summarized the pattern clearly. "We observed that cAMP responses across cells varied on a continuum," he said.

That range of responses may be important for understanding GLP-1 drug effects. If some neurons maintain the signal longer, they may continue contributing to appetite suppression. If other neurons fade quickly, the overall response may weaken in ways that matter for weight control.

The NIH announcement notes one possible reason for the temporary responses. Some neurons may internalize or degrade their **GLP-1 receptors**. In simple terms, the receptor that senses the drug may become less available at the cell surface, causing the internal signal to drop.

## The enzyme that shortens the effect

Inside cells, cAMP signals are shaped by enzymes that build them up and break them down. The NIH team focused on **PDE4**, an enzyme that degrades cAMP. When PDE4 is active, it can shorten the duration of the intracellular message.

This made PDE4 a logical target for testing. If cAMP helps drive semaglutide-induced weight loss, then slowing cAMP breakdown could change how long neurons stay responsive. The researchers tested that idea by selectively interfering with signaling molecules and observing which ones mattered most.

The experiments showed that disrupting the cAMP pathway had a strong effect. According to the NIH summary, semaglutide's weight-loss effects depended on increased cAMP in the area postrema. When that pathway was blocked or removed in the relevant neurons, the expected downstream effects were lost.

This gives scientists a more precise map of how semaglutide acts in the brain. The drug engages neurons in appetite circuits, then uses cAMP-dependent signaling inside those cells. That chain of events may help explain how a signal at the receptor becomes a change in body weight.

## How roflumilast changed the signal

To test whether the cAMP response could be extended, the researchers used **roflumilast**. This drug inhibits PDE4, the enzyme that breaks down cAMP. In the mouse brain tissue experiments, blocking PDE4 shifted neurons toward a more sustained cAMP response.

The finding is especially interesting because it shows that the signal's duration can be modified. Semaglutide increased cAMP and PDE4 inhibition helped keep that signal going in more cells. That suggests that intracellular signaling can influence how long a GLP-1 response lasts.

Still, the result needs careful interpretation. The NIH announcement describes this as a potential avenue for future treatment improvement. It does mean that people should combine drugs on their own. Drug combinations can have risks and this work was designed to study mechanisms in mice.

The study's value comes from its precision. It connects a specific drug, a specific brain region, a specific intracellular messenger and a specific enzyme. That gives researchers a testable path for future experiments.

## What this could mean for GLP-1 plateaus

Many people taking GLP-1 drugs experience a slowing of weight loss over time. The NIH team's findings offer one possible biological clue. If some neurons stop sustaining cAMP responses, the appetite-related signal may weaken or stabilize.

Lutas framed the broader motivation in terms of unanswered questions around drug response. "By digging into these mechanisms, we're beginning to answer some of these questions," he said.

The study suggests that **cAMP modulation** could someday help researchers explore ways to extend GLP-1 drug effects. The NIH announcement also notes that such approaches might reduce how often these medications must be administered. Those possibilities remain research goals at this stage.

For now, the work helps explain the biology behind a major class of medications. GLP-1 drugs influence behavior by acting on brain circuits that shape appetite. This study adds a closer view of the cellular signal that may help keep those circuits engaged.

## Why human studies still need to come next

The researchers studied **mice** and living mouse brain tissue. That makes the findings powerful for mechanism discovery, while leaving major clinical questions open. Human bodies, human brains and long-term treatment responses need direct study before the findings can guide care.

The NIH announcement also highlights a practical limit of the methods. The imaging approach allowed the team to examine intracellular signaling over a matter of hours. GLP-1 treatment in real life unfolds over days, weeks and months.

Future work will aim to track these intracellular effects over longer periods. That could show whether sustained cAMP signaling changes with repeated drug exposure. It could also help clarify how receptor internalization, receptor degradation and PDE4 activity shape longer-term responses.

The **Nature Metabolism** study gives scientists a sharper way to think about GLP-1 drugs. Semaglutide's effects involve more than a receptor turning on. The brain-cell response has timing, intensity and variation from neuron to neuron.

That variation may be where the next questions begin. If researchers can learn why some neurons sustain the signal and others fade, they may find safer and more precise ways to improve obesity therapeutics. For now, the discovery offers a detailed look at one of the brain's hidden links between a modern medicine and body weight.